Home

Felismer Lusta Aroma abl kinase vágy kedves gazdák

IJMS | Free Full-Text | c-Abl Tyrosine Kinase Is Regulated Downstream of  the Cytoskeletal Protein Synemin in Head and Neck Squamous Cell Carcinoma  Radioresistance and DNA Repair
IJMS | Free Full-Text | c-Abl Tyrosine Kinase Is Regulated Downstream of the Cytoskeletal Protein Synemin in Head and Neck Squamous Cell Carcinoma Radioresistance and DNA Repair

Opening the door to the development of novel Abl kinase inhibitors | Future  Medicinal Chemistry
Opening the door to the development of novel Abl kinase inhibitors | Future Medicinal Chemistry

JCI - Sequential ABL kinase inhibitor therapy selects for compound  drug-resistant BCR-ABL mutations with altered oncogenic potency
JCI - Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency

The role of non-receptor tyrosine kinases c-Abl and c-Src | Yosef Shaul's  Lab
The role of non-receptor tyrosine kinases c-Abl and c-Src | Yosef Shaul's Lab

Regulation of the c-Abl and Bcr–Abl tyrosine kinases | Nature Reviews  Molecular Cell Biology
Regulation of the c-Abl and Bcr–Abl tyrosine kinases | Nature Reviews Molecular Cell Biology

Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis: Cell
Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis: Cell

NMR reveals the allosteric opening and closing of Abelson tyrosine kinase  by ATP-site and myristoyl pocket inhibitors | PNAS
NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors | PNAS

BCR-ABL1 and the Philadelphia chromosome - Part 3: The BCR-ABL fusion  protein - YouTube
BCR-ABL1 and the Philadelphia chromosome - Part 3: The BCR-ABL fusion protein - YouTube

Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase: Cell
Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase: Cell

Differential signaling networks of Bcr–Abl p210 and p190 kinases in  leukemia cells defined by functional proteomics | Leukemia
Differential signaling networks of Bcr–Abl p210 and p190 kinases in leukemia cells defined by functional proteomics | Leukemia

Proposed mechanisms for the regulation of c-Abl tyrosine kinase. The... |  Download Scientific Diagram
Proposed mechanisms for the regulation of c-Abl tyrosine kinase. The... | Download Scientific Diagram

BCR-ABL signaling mimics growth factor activation. Growth factors are... |  Download Scientific Diagram
BCR-ABL signaling mimics growth factor activation. Growth factors are... | Download Scientific Diagram

A Novel Quantitative Kinase Assay Using Bacterial Surface Display and Flow  Cytometry | PLOS ONE
A Novel Quantitative Kinase Assay Using Bacterial Surface Display and Flow Cytometry | PLOS ONE

Cytoplasmic signalling by the c‐Abl tyrosine kinase in normal and cancer  cells - Sirvent - 2008 - Biology of the Cell - Wiley Online Library
Cytoplasmic signalling by the c‐Abl tyrosine kinase in normal and cancer cells - Sirvent - 2008 - Biology of the Cell - Wiley Online Library

Role of the ABL tyrosine kinases in the epithelial–mesenchymal transition  and the metastatic cascade | Cell Communication and Signaling | Full Text
Role of the ABL tyrosine kinases in the epithelial–mesenchymal transition and the metastatic cascade | Cell Communication and Signaling | Full Text

Bcr-Abl阻害 | Bcr-Abl Inhibition
Bcr-Abl阻害 | Bcr-Abl Inhibition

Conformational states dynamically populated by a kinase determine its  function | Science
Conformational states dynamically populated by a kinase determine its function | Science

BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia  chromosome positive chronic myeloid leukemia: a review. | Semantic Scholar
BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. | Semantic Scholar

PDF] Molecular Pathways Molecular Pathways : BCR-ABL | Semantic Scholar
PDF] Molecular Pathways Molecular Pathways : BCR-ABL | Semantic Scholar

Mechanism of action of BCR (breakpoint cluster region)-ABL (Abelson 1... |  Download Scientific Diagram
Mechanism of action of BCR (breakpoint cluster region)-ABL (Abelson 1... | Download Scientific Diagram

A Split-Abl Kinase for Direct Activation in Cells - ScienceDirect
A Split-Abl Kinase for Direct Activation in Cells - ScienceDirect

IJMS | Free Full-Text | Blockade of Y177 and Nuclear Translocation of Bcr- Abl Inhibits Proliferation and Promotes Apoptosis in Chronic Myeloid  Leukemia Cells
IJMS | Free Full-Text | Blockade of Y177 and Nuclear Translocation of Bcr- Abl Inhibits Proliferation and Promotes Apoptosis in Chronic Myeloid Leukemia Cells

BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction | Encyclopedia MDPI
BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction | Encyclopedia MDPI

STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of  chronic myelogenous leukaemia - The Lancet Oncology
STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia - The Lancet Oncology

Bcr-Abl tyrosine-kinase inhibitor - Wikipedia
Bcr-Abl tyrosine-kinase inhibitor - Wikipedia

Identification of the Direct Substrates of the ABL Kinase via Kinase Assay  Linked Phosphoproteomics with Multiple Drug Treatments | Journal of  Proteome Research
Identification of the Direct Substrates of the ABL Kinase via Kinase Assay Linked Phosphoproteomics with Multiple Drug Treatments | Journal of Proteome Research

Structure, Regulation, Signaling, and Targeting of Abl Kinases in Cancer -  Oliver Hantschel, 2012
Structure, Regulation, Signaling, and Targeting of Abl Kinases in Cancer - Oliver Hantschel, 2012

The SH2 Domain Regulates c-Abl Kinase Activation by a Cyclin-Like Mechanism  and Remodulation of the Hinge Motion | PLOS Computational Biology
The SH2 Domain Regulates c-Abl Kinase Activation by a Cyclin-Like Mechanism and Remodulation of the Hinge Motion | PLOS Computational Biology

Tyrosine-kinase inhibition in treatment of chronic myeloid leukaemia - The  Lancet
Tyrosine-kinase inhibition in treatment of chronic myeloid leukaemia - The Lancet